Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 8/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.73 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.73 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124051 | 0.86 | CYP26A1 (0.56) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL14957704 | 0.84 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL29567796 | 0.84 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL4986664 | 0.84 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL4986024 | 0.84 | RAB9A (0.58) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL9005850 | 0.83 | CYP26A1 (0.73) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| SCHEMBL10000095 | 0.83 | CYP26A1 (0.73) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL21020998 | 0.82 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL3739251 | 0.82 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 | |
| Talarozole SCHEMBL4984008 | 0.82 | CYP26A1 (1.00) | CYP26A1CYP3A4CYP2C9CYP2C8CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088062-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. | 2007-04-19 | — | — | US | claimed |
| EP-1037629-B1 | COMBINATION OF A RETINOIC ACID METABOLISM BLOCKING AGENT AND A TOCOPHEREOL | JANSSEN PHARMACEUTICA NV (BE) | 2004-10-27 | — | — | EP | claimed |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | claimed |
| US-20040024044-A1 | Exemestane as chemopreventing agent | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-05 | — | — | US | claimed |
| US-20030176419-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | VENET MARC GASTON (FR) | 2003-09-18 | — | — | US | claimed |
| EP-0907650-B1 | N- 4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2002-12-04 | — | — | EP | claimed |
| US-6265425-B1 | SIDE EFFECT REDUCTION; RETINOIC ACID METABOLISM BLOCKING AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 2001-07-24 | — | — | US | claimed |
| EP-1037629-A2 | COMBINATION OF A RETINOIC ACID METABOLISM BLOCKING AGENT AND A TOCOPHEREOL | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-09-27 | — | — | EP | claimed |
| US-6124330-A | A RETINOIC MIMETIC COMPOUND FOR TREATING A WARM-BLOODED ANIMAL SUFFERING FROM A DISEASE BY AN ABNORMAL PROLIFERATION AND/OR ABNORMAL DIFFERENTIATION OF NORMAL, PRENEOPLASTIC OR NEOPLASTIC CELLS | JANSSEN-CILAG S.A. (FR) | 2000-09-26 | — | — | US | claimed |
| WO-1999032098-A2 | COMBINATION OF A RAMBA AND A TOCOPHEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-07-01 | — | — | WO | claimed |
| EP-0907650-A1 | N- 4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-04-14 | — | — | EP | claimed |
| WO-1997049704-A1 | N-[4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-12-31 | — | — | WO | claimed |
| US-7378433-B2 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-27 | — | — | US | disclosed |
| US-20070088062-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. | 2007-04-19 | — | — | US | disclosed |
| US-7205312-B2 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| EP-1140192-B1 | USE OF THE CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AND CAPECITABINE FOR COMBINATION THERAPY IN NEOPLASIA | SEARLE LLC (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-1999032098-A2 | COMBINATION OF A RAMBA AND A TOCOPHEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176419-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP8B1, CYP2S1, CYP2B6 | CYP26A1 40/4885CYP3A4 15/4885CYP2C9 16/4885 |
| US-20070088062-A1 | N-[4-(heteroarylmethyl)phenyl]-heteroarylamines | CYP2S1, CYP2D6, CYP2C19 | CYP26A1 61/4885CYP3A4 5/4885CYP2C9 4/4885 |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | CYP19A1, BRCA1, ESR2 | CYP26A1 367/4885CYP3A4 994/4885CYP2C9 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.